Fig. 5.

Antiviral efficacy of astodrimer sodium and iota-carrageenan against SARS-CoV-2 (2019-nCoV/USA-WA1/2020) measured by a reduction in nucleocapsid (ng/mL), at Day 4 post-infection in human bronchial epithelial primary cells (HBEpC).

Astodrimer sodium (0, 1.1, 3.3 and 10 mg/mL) or iota-carrageenan (0, 6, 60 and 600 μg/mL) were added to cell cultures 1 h prior to infection.

A. Dose-response of astodrimer sodium antiviral activity. Points and error bars represent mean ± SD of triplicate readings. B. Dose-response of carrageenan antiviral activity. Points represent one replicate.

Dotted lines indicates level of inhibition achieved with positive control, SARS-CoV-2 pAb.